Date: 2012-07-18
Type of information: Plant acquisition
Acquired company: stake in Accera (USA)
Acquiring company: Nestle Health Sciences (Switzerland)
Amount: undisclosed
Terms:
Details: Nestlé Health Science has acquired a stake in a US firm Accera, to support the ongoing trials and rollout of the firm's key brand, Axona®, a medical food intended for the clinical dietary management of mild to moderate Alzheimer’s disease, already on the market in the USA. This acquisition is a strategic step forward in building up Nestle Health Science brain health portfolio.
Accera is a privately-held US-based company which specialises in the research, development and commercialisation of medical foods for neurodegenerative disorders like Alzheimer’s.
Accera’s ongoing clinical trials show that Axona® is metabolised by the liver to produce ketone bodies, which are naturally occurring compounds the brain can use as an alternative energy source. This results in improved memory and cognitive function in mild to moderate Alzheimer’s disease patients.
Axona® is already on the market in the US, prescribed to up to 30,000 people with mild to moderate Alzheimer’s.
Related: Nutrition
Neurodegenerative diseases
